ATLASRigel Pharmaceuticals (RIGL) earnings date: Nov 5, 2026
Rigel Pharmaceuticals (RIGL) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, after the close. Analysts expect EPS of $0.87.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on RIGL
| Last price | $50.47 (-1.6%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.7% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Rigel Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Rigel Pharmaceuticals reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Rigel Pharmaceuticals. You can switch it off at any time.
Alert me before RIGL reportsFree to start. Creating an account takes under a minute.
Notify me when Rigel Pharmaceuticals reports
Track RIGL free Add Rigel Pharmaceuticals to a free ATLAS watchlist and see its next report date in one place.
RIGL earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $0.87 |
| Last report | Aug 4, 2026 · Beat |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | +226.4% |
| Average move around a report | ±5.3% (last 5) |
| Sector | Healthcare · Biotechnology |
Rigel Pharmaceuticals earnings history: last 5 reports
Rigel Pharmaceuticals last reported on Aug 4, 2026: EPS of $0.88 against an estimate of -$0.08 (+1,200.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 4, 2026 | -$0.08 | $0.88 | +1,200.0% | Beat | +8.2% |
| Jun 16, 2026 | $1.65 | $1.67 | +1.2% | In line | -0.2% |
| May 5, 2026 | $0.87 | $0.44 | -49.4% | Miss | -9.7% |
| Apr 10, 2026 | -$0.16 | -$0.14 | +12.5% | Beat | -1.8% |
| Mar 11, 2026 | -$1.30 | -$1.72 | -32.3% | Miss | -6.5% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for RIGL
See the fair value, the probability range and the earnings history of Rigel Pharmaceuticals on its ATLAS page.
Rigel Pharmaceuticals (RIGL) stock analysisPlans from €3.99 a month.
Rigel Pharmaceuticals earnings: frequently asked questions
When does Rigel Pharmaceuticals (RIGL) report earnings?
Rigel Pharmaceuticals is scheduled to report on Thursday, November 5, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for RIGL?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $0.87 per share (USD). Estimates can change before the report.
How often does RIGL beat earnings estimates?
Of its last 5 reports with a recorded result, Rigel Pharmaceuticals beat the EPS estimate 2 times; the average surprise was +226.4%. Past results do not predict the next one.
How much does RIGL move around earnings?
Over its last 5 reports the stock moved an average of 5.3% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Rigel Pharmaceuticals beat earnings estimates last quarter?
Rigel Pharmaceuticals last reported on Aug 4, 2026: EPS of $0.88 against an estimate of -$0.08 (+1,200.0% surprise), a beat.
How much does RIGL usually move in a day?
On a normal trading day the ATLAS model puts RIGL’s one-day range at about ±2.7%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer